1h Free Analyst Time
The antibacterial drugs market is forecasted to grow by USD 7.63 billion during 2023-2028, accelerating at a CAGR of 3.2% during the forecast period. The report on the antibacterial drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of bacterial infections, growing awareness of various diseases and their treatment caused by bacteria, and rising aging population globally.
The antibacterial drugs market is segmented as below:
By Route Of Administration
- Intravenous
- Oral
- Others
By Drug Class
- B-lactam
- Quinolones
- Macrolids
- Tetracyclins
- Others
By Geographical Landscape
- Asia
- North America
- Europe
- Rest of World (ROW)
The report on the antibacterial drugs market covers the following areas:
- Antibacterial drugs market sizing
- Antibacterial drugs market forecast
- Antibacterial drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global antibacterial drugs market: Basilea Pharmaceutica Ltd., Bayer AG, Binnopharm Group LLC, Bristol Myers Squibb Co., Cipla Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Kyorin Pharmaceutical Co. Ltd., Lupin Ltd., Melinta Therapeutics LLC, Merck KGaA, Novartis AG, Paratek Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, SHIONOGI Co. Ltd., STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is rising potential of nanotechnology in combating infectious diseases."
According to the report, one of the major drivers for this market is the increasing prevalence of bacterial infections.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Basilea Pharmaceutica Ltd.
- Bayer AG
- Binnopharm Group LLC
- Bristol Myers Squibb Co.
- Cipla Inc.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Kyorin Pharmaceutical Co. Ltd.
- Lupin Ltd.
- Melinta Therapeutics LLC
- Merck KGaA
- Novartis AG
- Paratek Pharmaceuticals Inc.
- Pfizer Inc.
- Sanofi SA
- SHIONOGI Co. Ltd.
- STADA Arzneimittel AG
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
